The molecular chaperone Heat Shock Protein-90 (Hsp90) is essential for the folding and activity of an array of `client' proteins involved in signal transduction pathways. They are also responsible for many maladies including cancer, neurodegenerative, autoimmune and inflammatory diseases. Hsp90 inhibition strategies are currently being explored in these diseases in pre-clinical studies and clinical trials, however the optimal use of Hsp90-targeted therapeutics remains unknown. This is partly due to our limited knowledge of Hsp90 regulation in cells. Unraveling the detailed regulatory mechanisms of Hsp90 function in cells can provide new strategies to increase the cellular potency of Hsp90 inhibitors. Hsp90 chaperone function is coupled to its ATPase activity, which is regulated by co-chaperones and posttranslational modifications (PTMs). However, it is unclear how these regulatory components work together to fine tune Hsp90 function and also contribute towards drug sensitivity. During the past five years we have made major contributions towards the understanding of Hsp90 regulation by co-chaperones and PTMs. i) New co-chaperones: We have identified three new co-chaperones, FNIP1, 2 (collectively FNIPs) and Tsc1, that decelerate the chaperone cycle and facilitate chaper- oning of both kinase and non-kinase clients. They are regulated by PTMs (phosphoryla- tion, O-GlcNAcylation, SUMOlyation and ubiquitination). Their expression also enhances Hsp90 binding to drugs and consequently sensitizes cells to Hsp90 inhibitors. ii) Post- translational modification of Hsp90: Our work during the past decade on Hsp90 PTMs has redefined the regulation of its chaperone activity and revealed the reciprocal regula- tory mechanisms between client proteins, co-chaperones, and Hsp90. We have recently shown that loss of TSC1 co-chaperone leads to hypoacetylation of Hsp90 and elevated its ATPase activity. It also subsequently decreased Hsp90 binding to its inhibitors. Our long-term goal is to unravel the molecular mechanism of Hsp90 chaperone regulation in cells and regulatory factors enhancing cellular potency of Hsp90 inhibitors. Our strategy is to use biochemical, biophysical and cell-based assays to decipher the interconnectivi- ty and compensatory mechanisms between the co-chaperones and PTMs. Our vision is to utilize this information to dissect the intricate network of regulatory signals involved in fine tuning Hsp90 function and their impact towards cellular sensitivity to Hsp90 inhibi- tors.

Public Health Relevance

(RELEVANCE) The molecular chaperone Hsp90 is essential for maintaining protein homeostasis, which is critical in many maladies. This project will provide information on complex interplay between regulatory components of the Hsp90 chaperone in cells, which can also be uti- lized to enhance the sensitivity of cells to Hsp90 inhibitors.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Unknown (R35)
Project #
1R35GM139584-01
Application #
10086538
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Phillips, Andre W
Project Start
2021-01-01
Project End
2025-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
1
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Upstate Medical University
Department
Urology
Type
Schools of Medicine
DUNS #
058889106
City
Syracuse
State
NY
Country
United States
Zip Code
13210